Condition: Aortic Valve Regurgitation · Sponsor: Xijing Hospital
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
This description comes directly from the study's public registry record.
Rutao Wang, M.D, Ph.D · +86-15091095796 · rutaowang@qq.com
Always discuss trial participation with your own doctor first.
| Xijing Hospital | Xi'an, Shannxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06381271